Actinium Pharmaceuticals, Inc. (Delaware) (ATNM)
ATNM moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ATNM actually reacts to news — the realized, point-in-time move the market made, measured across 784 labeled events over the last three years with zero look-ahead.
ATNM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 764 |
| 30-min | 0.00% | 45% | 782 |
| 60-min | -0.08% | 45% | 783 |
| to close | 0.00% | 46% | 781 |
| Middle 50% of ATNM reactions | -1.44% to +1.18% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 784 |
Half of all Actinium Pharmaceuticals, Inc. (Delaware) news events land between -1.44% and +1.18% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ATNM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATNM's baseline. Nothing else.
Recent ATNM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Actinium Pharmaceuticals Announces Inducement Grants to New Employees | Press release | PR Newswire | — | — | |
| Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models | Press release | PR Newswire | +0.00% | +3.67% | |
| Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development | Press release | PR Newswire | +0.00% | +3.67% | |
| Form ARS Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +3.67% | |
| Form DEF 14A Actinium Pharmaceuticals For: Nov 25 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +3.67% | |
| Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer | Press release | PR Newswire | +0.00% | +11.58% | |
| Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer | Press release | PR Newswire | +0.00% | +11.58% | |
| Form 8-K Actinium Pharmaceuticals For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.67% | |
| Form S-8 Actinium Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.75% | |
| Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +2.82% | +16.04% | |
| Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update | Press release | PR Newswire | -0.90% | -5.41% | |
| Form 8-K Actinium Pharmaceuticals For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -5.41% | |
| Form 10-Q Actinium Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K Actinium Pharmaceuticals For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.98% | |
| Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models | Press release | PR Newswire | -2.00% | -7.20% | |
| Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer | Press release | PR Newswire | -2.00% | -7.20% | |
| Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development | Press release | PR Newswire | -1.59% | -6.35% | |
| Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates | Press release | PR Newswire | -1.59% | -6.35% | |
| Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs | Press release | PR Newswire | -1.59% | -6.35% | |
| Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice | Press release | PR Newswire | -1.59% | -6.35% | |
| Form 8-K Actinium Pharmaceuticals For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -6.35% | |
| Form 10-Q Actinium Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.67% | +1.51% | |
| Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization | Press release | PR Newswire | -3.08% | -4.62% | |
| Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting | Press release | PR Newswire | -6.58% | -7.89% | |
| Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting | Press release | PR Newswire | -6.58% | -7.89% | |
| Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting | Press release | PR Newswire | +2.97% | +7.92% | |
| Form 10-K Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.54% | |
| Form 8-K/A Actinium Pharmaceuticals For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting | Press release | PR Newswire | +0.43% | -6.09% | |
| Form 8-K Actinium Pharmaceuticals For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | -6.09% | |
| Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cance | Press release | PR Newswire | -0.99% | +0.00% | |
| Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium | Press release | PR Newswire | -0.71% | -2.14% | |
| Form 8-K Actinium Pharmaceuticals For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -4.17% | |
| Form 10-Q Actinium Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +5.07% | |
| Form ARS Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.73% | -2.94% | |
| Form DEF 14A Actinium Pharmaceuticals For: Nov 26 | SEC filing · Form DEF | SEC EDGAR | -0.73% | -2.94% | |
| Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications | Press release | PR Newswire | +0.00% | +0.00% | |
| Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference | Press release | PR Newswire | +1.42% | -2.13% | |
| Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molec | Press release | PR Newswire | -0.49% | -8.93% | |
| Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat | Press release | PR Newswire | -1.92% | +7.05% | |
| Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | PR Newswire | +5.91% | +7.33% | |
| Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat | Press release | PR Newswire | +1.01% | +8.05% | |
| Form 10-Q Actinium Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.84% | -5.16% | |
| Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Comb | Press release | PR Newswire | +3.15% | +2.52% | |
| Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Mole | Press release | PR Newswire | +0.33% | +1.67% | |
| Lifshitz Law PLLC Announces Investigations of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), SoundHound AI, Inc. (NASDAQ: SOUN), Solaris Energy Infrastructure, Inc. (NYSE: SEI), and Bakkt Holdings, Inc. (NYSE: BKKT) | Press release | ACCESS Newswire | +0.80% | +4.57% | |
| NYSE: ATNM Lawsuit Alert: Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) should Contact the Shareholders Foundation | Press release | ACCESS Newswire | -1.54% | -1.54% | |
| Form 10-Q Actinium Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.33% | +3.33% | |
| Form 8-K Actinium Pharmaceuticals For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +3.33% | +3.33% | |
| Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center | Press release | PR Newswire | +0.00% | -8.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATNM section they belong to.
Where else ATNM is measured.
ATNM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
| bluebird bio, Inc. (BLUE) | 787 | -0.01% | 46% |
| Heat Biologics, Inc. (HTBX) | 781 | -0.40% | 41% |
| HEMISPHERX BIOPHARMA (HEB) | 779 | -0.06% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Actinium Pharmaceuticals, Inc. (Delaware)'s median reaction calculated?
Every labeled ATNM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 784 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of ATNM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATNM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.